trial

Efficacy of Hi-tACS for Schizophrenia Negative Symptoms

NCTId NCT06888726
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Recruiting
Enrollment 60 (estimated)
Sponsored by Shanghai Mental Health Center
Primary completion 2025-11-30
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Recruiting
Enrollment
60 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2024-06-27
Primary completion
2025-11-30
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
High-intensity transcranial alternating current stimulation (Hi-tACS)

Sponsors

Shanghai Mental Health CenterLead Sponsor

Investigators

1
Qing FanPrincipal Investigator

Sites

1 total
Shanghai, China

Facts & assertions

4 sourced
Enrollment
60
Phase
NA
Primary Completion Date
2025-11-30
Status
RECRUITING
relationships
The graph out of here
drug
High-intensity transcranial alternating current stimulation (Hi-tACS)
drug
lead_sponsor
Shanghai Mental Health Center
company
indication
Schizophrenia
indication
Transcranial Alternating Current Stimulation
indication
Schizophrenia; Negative Type
indication
investigator
Qing Fan
person